Evaluation of Clinical Assessment, Mammography, and Ultrasonography in Diagnosis of Benign and Malignant Breast Lesions and Determining Their Cost-Effectiveness

Akbari, Mohammad Taghi; Nabatzade, Mojgan; Azargashb, Enzollah; Nafissi, Nahid; Haghighatkhah, Hamid Reza; Moayeri, Hassan; Shakeri, Jafar; Nabatzade, Roya; Nabatzade, Mojde; Zoghipour, Somaye; Najafizade, Sepehr; Najafizade, Arash; Akbari, Mohammad Esmaeil

doi:10.5812/ijcm.69683

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Akbari et al (31) reported that more than 50% of the diagnostic imaging in primary breast cancer diagnosis are not matched with pathologic report as the golden standard of cancer diagnosis due to lack of spending time by radiologists and quality of their equipment.…”

Section: Discussion About Resultsmentioning

confidence: 99%

Induced Demand in Cancer Diagnosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Context: Supplier-induced demand (SID) is an essential concept in health economics related to the diagnosis of different types of cancer and related expenditures. The current review considered studies on induced demand in cancer diagnosis. Evidence Acquisition: This systematic review investigated the induced diagnosis of cancer in four well-known databases (Scopus, Science Direct, Web of Science, and PubMed) from January 1980 to July 2019 using the keywords “induced demand,” “cancer,” and “diagnosis”. References of the studies found through the original search were also considered for analysis. Results: No studies focused on SID in cancer diagnosis could be found, thus indicating a significant deficiency in the discussion of SID in cancer diagnosis studies. Therefore, the terms most relevant to the concept of SID in cancer diagnosis were examined. Finally, 24 factors were categorized into three groups: economic, socio-cultural, and structural. The majority of evidence for the probability of SID in cancer diagnosis is related to overdiagnosis or early diagnosis caused by unnecessary screening (57.14% of reviewed articles) and the neglect of clinical practice guidelines (42.8% of reviewed articles), mainly by diagnostic imaging. Conclusions: Research focused explicitly on SID in cancer diagnosis is needed. Moreover, economic, social, and structural reforms related to the factors that connect overuse, overdiagnosis, and unnecessary services to cancer diagnosis are required to control costs and harm and provide the best benefits to patients.

show abstract

Section: Discussion About Resultsmentioning

confidence: 99%

Induced Demand in Cancer Diagnosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

et al. 2021

View full text Add to dashboard Cite

Background. Understanding the cost of delivering breast cancer (BC) care in low-and middle-income countries (LMICs) is critical to guide effective care delivery strategies. This scoping review summarizes the scope of literature on the costs of BC care in LMICs and characterizes the methodological approaches of these economic evaluations. Materials and Methods. A systematic literature search was performed in five databases and gray literature up to March 2020. Studies were screened to identify original articles that included a cost outcome for BC diagnosis or treatment in an LMIC. Two independent reviewers assessed articles for eligibility. Data related to study characteristics and methodology were extracted. Study quality was assessed using the Drummond et al. checklist.Results. Ninety-one articles across 38 countries were included. The majority (73%) of studies were published between 2013 and 2020. Low-income countries (2%) and countries in Sub-Saharan Africa (9%) were grossly underrepresented. The majority of studies (60%) used a health care system perspective. Time horizon was not reported in 30 studies (33%). Of the 33 studies that estimated the cost of multiple steps in the BC care pathway, the majority (73%) were of high quality, but studies varied in their inclusion of nonmedical direct and indirect costs. Conclusion.There has been substantial growth in the number of BC economic evaluations in LMICs in the past decade, but there remain limited data from low-income countries, especially those in Sub-Saharan Africa. BC economic evaluations should be prioritized in these countries. Use of existing frameworks for economic evaluations may help achieve comparable, transparent costing analyses. The Oncologist 2021;26:1-12 Implications for Practice: There has been substantial growth in the number of breast cancer economic evaluations in lowand middle-income countries (LMICs) in the past decade, but there remain limited data from low-income countries. Breast cancer economic evaluations should be prioritized in low-income countries and in Sub-Saharan Africa. Researchers should strive to use and report a costing perspective and time horizon that captures all costs relevant to the study objective, including those such as direct nonmedical and indirect costs. Use of existing frameworks for economic evaluations in LMICs may help achieve comparable, transparent costing analyses in order to guide breast cancer control strategies.

show abstract

Evaluation of Clinical Assessment, Mammography, and Ultrasonography in Diagnosis of Benign and Malignant Breast Lesions and Determining Their Cost-Effectiveness

Cited by 2 publications

References 10 publications

Induced Demand in Cancer Diagnosis

Induced Demand in Cancer Diagnosis

Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review

Contact Info

Product

Resources

About